US Treasury Proposes Adding Biotech to Outbound Investment Rules as China Urges Halt
Extending restrictions from computing power into pharmaceutical research capability means the target of US-China friction is shifting from physical equipment toward irreplaceable knowledge assets. The carve-out reveals how US policymakers balance economic pressure against pharmaceutical revenue in China.